Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APN401 in Advanced Solid Tumors (PALINDROM)
NCT06172894Phase 1Completed
- Sponsor
- invIOs
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of APN401 in solid tumor (advanced stage) (2 arms), sponsored by invIOs. Primary endpoints: Incidence of Treatment Emergent Adverse Events and Serious Adverse Events, Occurrence of Dose Limiting Toxicities at 21 days and 1 more. Started Aug 2023; status: completed.
02
Drugs
APN401
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06172894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06172894.